[Cardiotropic properties of lithium oxybutyrate in an experiment and in the clinic].
Lithium oxybutyrate was shown to exert pronounced coronarolytic effects, to increase volume velocity of the coronary blood flow, to improve blood supply to ischemic myocardial areas thereby providing oxygen reserve. Lithium oxybutyrate improves the functional state of the ischemic focus, limits zone of experimental myocardial necroses, exerts an antifibrillatory action, increases pain sensitivity threshold. A high efficacy of the drug was established during clinical study in patients with cardiac rhythm disorders.
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use; D005117:Cardiac Complexes, Premature / Q000188:drug therapy; D002415:Cats; D003327:Coronary Disease / Q000188:drug therapy; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D005260:Female; D006321:Heart / Q000187:drug effects*; D006801:Humans; D006885:Hydroxybutyrates / Q000494:pharmacology* / Q000627:therapeutic use; D008094:Lithium / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D009449:Neurocirculatory Asthenia / Q000188:drug therapy; D009942:Organometallic Compounds; D011817:Rabbits; D051381:Rats; D014693:Ventricular Fibrillation / Q000188:drug therapy
D000889:Anti-Arrhythmia Agents; D006885:Hydroxybutyrates; D009942:Organometallic Compounds; C022826:lithium hydroxybutyrate; D008094:Lithium
Kardiotropnye svoĭstva litiia oksibutirata v éksperimente i klinike.